Safety Study for Beta Thalassemia Subjects on PTG-300
NCT04054921 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34
Last updated 2021-07-16
Summary
In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.
Conditions
- β-thalassemia
- Ineffective Erythropoiesis
Interventions
- DRUG
-
PTG-300
PTG-300 is a hepcidin Mimetic
Sponsors & Collaborators
-
Protagonist Therapeutics, Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 12 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-05-10
- Primary Completion
- 2020-07-31
- Completion
- 2020-07-31
- FDA Drug
- Yes
Countries
- United States
- Greece
- Lebanon
- Malaysia
- Thailand
- Tunisia
- Turkey (Türkiye)
- United Kingdom
Study Locations
More Related Trials
-
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants
NCT01745120 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia
NCT03207009 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype
NCT02906202 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia
NCT05773729 ·Status: RECRUITING ·Phase: NA
-
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
NCT05864170 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
NCT00005934 ·Status: COMPLETED ·Phase: PHASE2
-
PTG-300 in Subjects With Hereditary Hemochromatosis
NCT04202965 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL)
NCT03275051 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.
NCT05567458 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Gene Therapy for Transfusion Dependent Beta-thalassemia
NCT02453477 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
NCT02633943 ·Status: ACTIVE_NOT_RECRUITING
-
An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia
NCT06308159 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major
NCT00336362 ·Status: COMPLETED ·Phase: NA
-
A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia
NCT03271541 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major
NCT02342145 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)
NCT01749540 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants
NCT05757245 ·Status: RECRUITING ·Phase: PHASE1
-
A Long-term Follow-up Study in Participants Who Received CS-101
NCT06479616 ·Status: RECRUITING ·Phase: NA
-
Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
NCT01740531 ·Status: COMPLETED ·Phase: PHASE3
-
Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector
NCT03351829 ·Status: UNKNOWN ·Phase: NA
-
A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
NCT05762510 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
NCT02604433 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
NCT06271512 ·Status: RECRUITING
-
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
NCT06302491 ·Status: RECRUITING ·Phase: PHASE2
-
Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand
NCT01609595 ·Status: COMPLETED ·Phase: PHASE2